Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

作者
Floriana Morgillo,Morena Fasano,Carminia Maria Della Corte,Ferdinando Carlo Sasso,Federica Papaccio,Giuseppe Viscardi,Giovanna Esposito,Raimondo Di Liello,Nicola Normanno,Annalisa Capuano,Liberato Berrino,Giovanni Vicidomini,Alfonso Fiorelli,Mario Santini,Fortunato Ciardiello
出处
期刊:ESMO open [Elsevier BV]
卷期号:2 (2): e000132-e000132 被引量:76
标识
DOI:10.1136/esmoopen-2016-000132
摘要

PURPOSE: Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be used in non-diabetic patients still remains to be defined. The phase I-II trial METformin in Advanced Lung cancer (METAL) was designed to identify the maximum tolerated dose and to evaluate safety and activity of metformin combined with erlotinib in second-line treatment of patients with stage IV NSCLC, whose tumours harbour the WT EGFR gene. PATIENTS AND METHODS: We report results from the safety run-in part designed to detect acute toxicities, to study pharmacokinetics and to identify the recommended phase II dose (RPD) to be used for the following phase of the study. In the run-in phase, metformin treatment was administered according to a dose escalation scheme and, subsequently, combined with erlotinib. RESULTS: Twelve patients were enrolled. Common adverse events were diarrhoea, decreased appetite, abdominal pain, vomiting and skin toxicity, mostly reversible with symptomatic medical treatment. Dose-limiting toxicities were vomiting and diarrhoea registered in the initial cohort receiving metformin 2000 mg plus erlotinib at 150 mg die, which was declared the maximum administered dose. Only one of nine patients treated at the next lower dose of 1500 mg of metformin plus erlotinib at 150 mg experienced G3 gastrointestinal toxicity. Metformin plasma-concentration profile confirmed the trend already observed in non-diabetic population. Glycemic profiles showed stability of the blood glucose level within the physiological range for non-diabetic subjects. At a follow-up of 30 weeks, six (50%) patients experienced a disease control (5 SD and 1 partial response). CONCLUSIONS: The RP2D of metformin dose was defined at 1500 mg/day to be combined with erlotinib 150 mg. TRIAL REGISTRATION NUMBER: EudraCT number: 2014-000349-59.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谷音给谷音的求助进行了留言
1秒前
1秒前
元吉的应助被Mingjie123采纳,获得10
1秒前
2秒前
4秒前
发了十篇Nature完成签到,获得积分10
5秒前
Tuniverse_发布了新的文献求助10
6秒前
7秒前
喂喂喂发布了新的文献求助10
8秒前
田様的应助被微微采纳,获得10
8秒前
pp完成签到,获得积分10
8秒前
hygogogo完成签到,获得积分20
9秒前
顺利安发布了新的文献求助10
9秒前
科研通AI6.3的应助被Lion采纳,获得30
10秒前
10秒前
科研通AI2S的应助被十七采纳,获得10
11秒前
慕青的应助被愤怒的千易采纳,获得10
11秒前
11秒前
学不会完成签到,获得积分10
11秒前
许俊梁发布了新的文献求助10
11秒前
12秒前
13秒前
阿金发布了新的文献求助10
13秒前
可爱的函函的应助被耍酷思菱采纳,获得10
15秒前
顺利安完成签到,获得积分10
15秒前
丰富的诗蕾完成签到,获得积分20
16秒前
523发布了新的文献求助10
16秒前
17秒前
小蘑菇的应助被笑点低的海冬采纳,获得10
17秒前
852的应助被笑点低的海冬采纳,获得10
17秒前
17秒前
17秒前
大模型的应助被笑点低的海冬采纳,获得10
17秒前
归期关注了科研通微信公众号
17秒前
淡然的舞仙完成签到,获得积分10
17秒前
17秒前
18秒前
lxr完成签到,获得积分10
19秒前
CodeCraft的应助被七七采纳,获得10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621